FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3188203792> ?p ?o ?g. }

• W3188203792 endingPage "e2119151" @default.
• W3188203792 startingPage "e2119151" @default.
• W3188203792 abstract "Antiviral treatment of influenza is recommended for patients with influenza-like illness during periods of community cocirculation of influenza viruses and SARS-CoV-2; however, questions remain about which treatment is associated with the best outcomes and fewest adverse events.To compare the efficacy and safety of neuraminidase inhibitors and the endonuclease inhibitor for the treatment of seasonal influenza among healthy adults and children.Medline, Embase, and the Cochrane Register of Clinical Trials were searched from inception to January 2020 (the last search was updated in October 2020).Included studies were randomized clinical trials conducted among patients of all ages with influenza treated with neuraminidase inhibitors (ie, oseltamivir, peramivir, zanamivir, or laninamivir) or an endonuclease inhibitor (ie, baloxavir) compared with other active agents or placebo.Two investigators identified studies and independently abstracted data. Frequentist network meta-analyses were performed; relative ranking of agents was conducted using P-score probabilities. Quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations criteria. Data were analyzed in October 2020.The time to alleviation of influenza symptoms (TTAS), complications of influenza, and adverse events (total adverse events, nausea, and vomiting).A total of 26 trials were identified that investigated antiviral drugs at high or low doses; these trials included 11 897 participants, among whom 6294 (52.9%) were men and the mean (SD) age was 32.5 (16.9) years. Of all treatments comparing with placebo in efficacy outcomes, high-quality evidence indicated that zanamivir was associated with the shortest TTAS (hazard ratio, 0.67; 95% CI, 0.58-0.77), while baloxavir was associated with the lowest risk of influenza-related complications (risk ratio [RR], 0.51; 95% CI, 0.32-0.80) based on moderate-quality evidence. In safety outcomes, baloxavir was associated with the lowest risk of total adverse events (RR, 0.84; 95% CI, 0.74-0.96) compared with placebo based on moderate-quality evidence. There was no strong evidence of associations with risk of nausea or vomiting among all comparisons, except for 75 mg oseltamivir, which was associated with greater occurrence of nausea (RR, 1.82; 95% CI, 1.38-2.41) and vomiting (RR, 1.88; 95% CI, 1.47-2.41).In this systematic review and network meta-analysis, all 4 antiviral agents assessed were associated with shortening TTAS; zanamivir was associated with the shortest TTAS, and baloxavir was associated with reduced rate of influenza-related complications." @default.
• W3188203792 created "2021-08-16" @default.
• W3188203792 creator A5013228619 @default.
• W3188203792 creator A5021798192 @default.
• W3188203792 creator A5037962392 @default.
• W3188203792 creator A5054932756 @default.
• W3188203792 creator A5089954733 @default.
• W3188203792 date "2021-08-13" @default.
• W3188203792 modified "2023-10-07" @default.
• W3188203792 title "Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children" @default.
• W3188203792 cites W142853197 @default.
• W3188203792 cites W1965226808 @default.
• W3188203792 cites W1971895240 @default.
• W3188203792 cites W1982967337 @default.
• W3188203792 cites W2004554957 @default.
• W3188203792 cites W2006670989 @default.
• W3188203792 cites W2006934056 @default.
• W3188203792 cites W2010284659 @default.
• W3188203792 cites W2011162259 @default.
• W3188203792 cites W2017196313 @default.
• W3188203792 cites W2026201313 @default.
• W3188203792 cites W2026359119 @default.
• W3188203792 cites W2039339516 @default.
• W3188203792 cites W2046938649 @default.
• W3188203792 cites W2058987495 @default.
• W3188203792 cites W2066655598 @default.
• W3188203792 cites W2072658090 @default.
• W3188203792 cites W2074147400 @default.
• W3188203792 cites W2088095316 @default.
• W3188203792 cites W2091808438 @default.
• W3188203792 cites W2098923148 @default.
• W3188203792 cites W2099698280 @default.
• W3188203792 cites W2101366722 @default.
• W3188203792 cites W2107485527 @default.
• W3188203792 cites W2111999709 @default.
• W3188203792 cites W2112164609 @default.
• W3188203792 cites W2119605658 @default.
• W3188203792 cites W2122256368 @default.
• W3188203792 cites W2123074327 @default.
• W3188203792 cites W2128464913 @default.
• W3188203792 cites W2130441728 @default.
• W3188203792 cites W2144625636 @default.
• W3188203792 cites W2150047295 @default.
• W3188203792 cites W2155798268 @default.
• W3188203792 cites W2160146630 @default.
• W3188203792 cites W2163949383 @default.
• W3188203792 cites W2170704405 @default.
• W3188203792 cites W2316432487 @default.
• W3188203792 cites W2334261876 @default.
• W3188203792 cites W2396644784 @default.
• W3188203792 cites W2475523245 @default.
• W3188203792 cites W2536156380 @default.
• W3188203792 cites W2672015598 @default.
• W3188203792 cites W2748628185 @default.
• W3188203792 cites W2759397782 @default.
• W3188203792 cites W2766211624 @default.
• W3188203792 cites W2781116905 @default.
• W3188203792 cites W2795706728 @default.
• W3188203792 cites W2797275678 @default.
• W3188203792 cites W2892275685 @default.
• W3188203792 cites W2904354111 @default.
• W3188203792 cites W2912478845 @default.
• W3188203792 cites W2916184559 @default.
• W3188203792 cites W2995730965 @default.
• W3188203792 cites W3028642473 @default.
• W3188203792 cites W3033918806 @default.
• W3188203792 cites W3057702561 @default.
• W3188203792 cites W4210868240 @default.
• W3188203792 cites W4229846538 @default.
• W3188203792 cites W4241655535 @default.
• W3188203792 cites W4242912620 @default.
• W3188203792 cites W4244191271 @default.
• W3188203792 cites W4244858133 @default.
• W3188203792 cites W4245631420 @default.
• W3188203792 cites W4245773446 @default.
• W3188203792 cites W4295632655 @default.
• W3188203792 doi "https://doi.org/10.1001/jamanetworkopen.2021.19151" @default.
• W3188203792 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8363918" @default.
• W3188203792 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34387680" @default.
• W3188203792 hasPublicationYear "2021" @default.
• W3188203792 type Work @default.
• W3188203792 sameAs 3188203792 @default.
• W3188203792 citedByCount "28" @default.
• W3188203792 countsByYear W31882037922021 @default.
• W3188203792 countsByYear W31882037922022 @default.
• W3188203792 countsByYear W31882037922023 @default.
• W3188203792 crossrefType "journal-article" @default.
• W3188203792 hasAuthorship W3188203792A5013228619 @default.
• W3188203792 hasAuthorship W3188203792A5021798192 @default.
• W3188203792 hasAuthorship W3188203792A5037962392 @default.
• W3188203792 hasAuthorship W3188203792A5054932756 @default.
• W3188203792 hasAuthorship W3188203792A5089954733 @default.
• W3188203792 hasBestOaLocation W31882037921 @default.
• W3188203792 hasConcept C126322002 @default.
• W3188203792 hasConcept C134164806 @default.
• W3188203792 hasConcept C142724271 @default.
• W3188203792 hasConcept C159047783 @default.
• W3188203792 hasConcept C168563851 @default.

• next